Question

The client is developing a braf inhibitor which is currently in a phase i trial. They want to understand the opportunities for their drug in solid tumors. How would you identify and prioritize opportunities/indications with in solid tumors for the braf inhibitor in order to arrive at the most attractive 3-5 opportunities. The approach would need to include scientific, clinical and commercial parameters.

Answer 1

vajdjdfbtgbjfxjrslutvnmihjdjdj

$1161 = 19$